[1] Lim H, Devesa SS, Sosa JA, et al.Trends in thyroid cancer incidence and mortality in the United States, 1974-2013[J]. JAMA,2017,317(13):1338-1348.
[2] Wendler J, Kroiss M, Gast K, et al.Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany[J]. Eur J Endocrinol,2016,175(6):521-529.
[3] Segerhammar I, Larsson C, Nilsson IL, et al.Anaplastic carcinoma of the thyroid gland: treatment and outcome over 13 years at one institution[J]. J Surg Oncol,2012, 106(8):981-986.
[4] Ranganath R, Shah MA, Shah AR.Anaplastic thyroid cancer[J]. Curr Opin Endocrinol Diabetes Obes,2015,22(5):387-391.
[5] Smallridge RC, Ain KB, Asa SL, et al.American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer[J]. Thyroid,2012,22(11):1104-1139.
[6] Landa I, Ibrahimpasic T, Boucai L, et al.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers[J]. J Clin Invest,2016,26(3):1052-1066.
[7] Smallridge RC, Marlow LA, Copland JA.Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies[J]. Endocr Relat Cancer,2009,16(1):17-44.
[8] Jeon MJ, Chun SM, Kim D, et al.Genomic alterations of anaplastic thyroid carcinoma detected by targeted massive parallel sequencing in a BRAF(V600E) mutation-prevalent area[J]. Thyroid,2016,26(5):683-690.
[9] Liu Z, Hou P, Ji M, et al.Highly prevalent genetic altera-tions in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers[J]. J Clin Endocrinol Metab,2008,93(8):3106-3116.
[10] Lee J, Hwang JA, Lee EK.Recent progress of genome study for anaplastic thyroid cancer[J]. Genomics Inform,2013,11(2):68-75.
[11] Ensinger C, Spizzo G, Moser P, et al.Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas[J]. Ann N Y Acad Sci,2004,1030:69-77.
[12] Arora A, Scholar EM.Role of tyrosine kinase inhibitors in cancer therapy[J]. J Pharmacol Exp Ther,2005,315(3):971-979.
[13] Kim S, Yazici YD, Calzada G, et al.Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice[J]. Mol Cancer Ther,2007,6(6):1785-1792.
[14] Brose MS, Nutting CM, Jarzab B, et al.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet,2014,384(9940):319-328.
[15] Savvides P, Nagaiah G, Lavertu P, et al.Phase Ⅱ trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid[J]. Thyroid,2013,23(5):600-604.
[16] Ha HT, Lee JS, Urba S, et al.A phase Ⅱ study of imatinib in patients with advanced anaplastic thyroid cancer[J]. Thyroid,2010,20(9):975-980.
[17] Xu CF, Xue Z, Bing N, et al.Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer[J]. Ann Oncol,2012,23(9):2470-2471.
[18] Bible KC, Suman VJ, Menefee ME, et al.A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer[J]. J Clin Endocrinol Metab,2012,97(9):3179-3184.
[19] McLarnon A. Thyroid cancer: Pazopanib alone is not effective against anaplastic thyroid cancer[J]. Nat Rev Endocrinol,2012,8(10):565.
[20] Isham CR, Bossou AR, Negron V, et al. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer[J]. Sci Transl Med,2013,5(166):166ra3.
[21] Miyake H, Miyazaki A, Imai S, et al.Early tumor shrinka-ge under treatment with first-line tyrosine kinase inhibitors as a predictor of overall survival in patients with metastatic renal cell carcinoma: a retrospective multi-institutional study in Japan[J]. Target Oncol,2016,11(2):175-182.
[22] Di Desidero T, Fioravanti A, Orlandi P, et al.Antiproli-ferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1[J]. J Clin Endocrinol Metab,2013,98(9):E1465-E1473.
[23] Bikas A, Kundra P, Desale S, et al.Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer[J]. Eur J Endocrinol,2016,174(3):373-380.
[24] Glen H, Mason S, Patel H, et al.E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion[J]. BMC Cancer,2011,11:309.
[25] Schlumberger M, Tahara M, Wirth LJ, et al.Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med,2015,372(7):621-630.
[26] Takahashi S, Tahara M, Kiyota N, et al. Phase Ⅱ study of lenvatinib(LEN), a multi-targeted tyrosine kinase inhibitor, in patients(PTS) with all histologic subtypes of advanced thyroid cancer[J]. Ann Oncol,2014,25(suppl 4): iv343-iv344.
[27] Tahara M, Kiyota N, Yamazaki T, et al.Lenvatinib for anaplastic thyroid Cancer[J]. Front Oncol,2017,7:25.
[28] Lim SM, Chang H, Yoon MJ, et al.A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes[J]. Ann Oncol,2013,24(12):3089-3094.
[29] Wagle N, Grabiner BC, van Allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer[J]. N Engl J Med,2014,371(15):1426-1433.
[30] Bollag G, Hirth P, Tsai J, et al.Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma[J]. Nature,2010,467(7315):596-599.
[31] Rosove MH, Peddi PF, Glaspy JA.BRAF V600E inhibition in anaplastic thyroid cancer[J]. N Engl J Med,2013, 368(7):684-685.
[32] Hyman DM, Puzanov I, Subbiah V, et al.Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations[J]. N Engl J Med,2015,373(8):726-736.
[33] Pennell NA, Daniels GH, Haddad RI, et al.A phase Ⅱ study of gefitinib in patients with advanced thyroid cancer[J]. Thyroid,2008,18(3):317-323.
[34] Tozer GM, Kanthou C, Baguley BC.Disrupting tumour blood vessels[J]. Nat Rev Cancer,2005,5(6):423-435.
[35] Dark GG, Hill SA, Prise VE, et al.Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature[J]. Cancer Res,1997,57(10):1829-1834.
[36] Sosa JA, Elisei R, Jarzab B, et al.Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma[J]. Thyroid,2014,24(2):232-240.
[37] Mooney CJ, Nagaiah G, Fu P, et al.A phase Ⅱ trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome[J]. Thyroid,2009,19(3):233-240.
